Scientific Reports (Jun 2022)

Mutations in the miR-142 gene are not common in myeloproliferative neoplasms

  • Paulina Galka-Marciniak,
  • Zuzanna Kanduła,
  • Adrian Tire,
  • Wladyslaw Wegorek,
  • Kinga Gwozdz-Bak,
  • Luiza Handschuh,
  • Maciej Giefing,
  • Krzysztof Lewandowski,
  • Piotr Kozlowski

DOI
https://doi.org/10.1038/s41598-022-15162-1
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Recent data indicate that MIR142 is the most frequently mutated miRNA gene and one of the most frequently mutated noncoding elements in all cancers, with mutations occurring predominantly in blood cancers, especially diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Functional analyses show that the MIR142 alterations have profound consequences for lympho- and myelopoiesis. Furthermore, one of the targets downregulated by miR-142-5p is CD274, which encodes PD-L1 that is elevated in many cancer types, including myeloproliferative neoplasms (MPNs). To extend knowledge about the occurrence of MIR142 mutations, we sequenced the gene in a large panel of MPNs [~ 700 samples, including polycythemia vera, essential thrombocythemia, primary myelofibrosis (PMF), and chronic myeloid leukemia], neoplasm types in which such mutations have never been tested, and in panels of acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). We identified 3 mutations (one in a PMF sample and two others in one CLL sample), indicating that MIR142 mutations are rare in MPNs. In summary, mutations in MIR142 are rare in MPNs; however, in specific subtypes, such as PMF, their frequency may be comparable to that observed in CLL or AML.